trending Market Intelligence /marketintelligence/en/news-insights/trending/b8j1uWOwARmhAlftZDHVUg2 content esgSubNav
In This List

Former Juniper exec joins 2X Oncology as CEO

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Former Juniper exec joins 2X Oncology as CEO

2X Oncology Inc. named George Elston as CEO and a board member.

Elston was previously CFO of Juniper Pharmaceuticals Inc.

2X Oncology is a clinical stage company developing targeted therapeutics that leverage proprietary drug response predictor companion diagnostic technology to address unmet needs in women's cancer.